Stratification of Risk of Diabetes in Early Pregnancy (STRiDE)

Hyperglycaemia in Pregnancy or Gestational Diabetes Mellitus (GDM) is one of the most common obstetric medical conditions which when undetected can cause significant adverse outcomes for the mother and the offspring. Diagnosis is typically made between 24-28 weeks of pregnancy using oral glucose tolerance test (OGTT). Therefore, some damage might have already happened prior to detection. Although universal screening is recommended by many guidelines, this is not uniformly followed across the world, partly because of doubts about cost-effectiveness. Only selective screening is followed based on presence of at least one of the high risk factors (age, BMI, previous history, etc). This strategy can miss up to 50% of GDM. In addition, no data exists in India and Kenya. In low and middle-income countries (LMICs), where majority live in rural settings, the major limitations are difficulty in conducting OGTT, which requires prompt access to laboratory facilities. Combining the clinical and easily analysable biochemical markers (composite risk score) could improve the prediction and if proven, could help to prevent the onset of GDM. Fasting glucose levels (at non-diabetes levels) in early pregnancy could predict future GDM. HbA1c in early pregnancy can be a better marker as it can be done point-of-care and does not require patients to be in a fasting state. The overall objective of the proposed project is to develop a composite risk score to predict GDM in early pregnancy using a combination of easily identifiable risk factors such as age, BMI, family history of Type 2 Diabetes along with HbA1c in Indians and Kenyans. The project will recruit pregnant women in early pregnancy from South India (n=3400) and Western Kenya (n=4000). Contribution of individual risk factors as well as the composite risk score on the risk of developing GDM will be assessed. Detailed health economic analyses will enable policy makers to make informed decision based on local data.

Study Overview

• Status: Unknown
• Conditions: Gestational Diabetes Mellitus

Detailed Description

High glucose level in Pregnancy or Gestational Diabetes Mellitus (GDM) is one of the most common medical conditions during pregnancy. When undetected, it can cause significant harm for the pregnant women and her offspring. GDM can affect 5-25% of all pregnant women. It depends on the population and where the boundary is drawn between normal and abnormal glucose levels.

Certain ethnic minority groups are considered at high-risk for developing GDM, including Indians. It is estimated >15% of pregnancies are affected by GDM in India. The immediate risks of untreated GDM are high rates of pre-eclampsia, higher caesarean section rates and psychological effects such as anxiety and depression. Women who develop GDM have a 7-8 times higher life-time risk of type 2 diabetes (T2D). Similarly, the immediate risks to the children are being too big or too small, shoulder damage during labour, low glucose levels or jaundice at birth, difficulty in breathing and in rare cases stillbirth. In the long term, the risk of obesity and T2D is also higher.

The diagnosis of GDM is usually made between 24-28 weeks of pregnancy using a glucose drink test called oral glucose tolerance test (OGTT). Although treatment can improve the outcomes, some of the damage may have already been done before the detection of GDM. Therefore, screening to detect high glucose level in pregnancy seems beneficial. However, there can be harms as well as benefits in screening programmes. Therefore a balance should be achieved between identifying women whose blood glucose level is high enough to cause harm and those with glucose level that would not cause harm. Currently, it is recommended that all pregnant women should be screened for GDM if they belong to a high-risk ethnic population. However, conducting OGTT in India is challenging, as this test requires pregnant women present themselves to a laboratory facility in a fasting state.

In many countries, women are selected for OGTT based on the presence of at least one of the high risk factors such as higher body weight, older age and family history of T2D. However, this selection method can miss up to 50% of women who may develop GDM. The aim of the study is to develop a risk score in early pregnancy based on a combination of these risk factors that can be collected easily along with a simple finger prick average blood glucose test (called HbA1c). The efficiency of different levels of this combined risk score will be tested against the risk of developing GDM in the later part of pregnancy.

Cost effectiveness analysis will also be conducted to identify at what risk level screening can be recommended in India. An accurate score that can safely exclude women at low risk of developing GDM will have significant benefits to the pregnant women. They can be safely reassured. Avoiding the need for OGTT will have significant time and cost benefits. In contrast, if the score identifies them as at high-risk, healthy eating and appropriate life style advice can reduce their risk of developing GDM in later pregnancy.

• Study Type: Observational
• Enrollment (Anticipated): 7400

Contacts and Locations

Study Locations

• India
  • Tamil Nadu
    • Chennai, Tamil Nadu, India, 600086
      • Recruiting
      • Madras Diabetes Research Foundation
      • Contact: Deepa Mohan, PhD; Phone Number: 00914443968888; Email: deepa.mohan1@gamil.com
      • Contact: Bhavadharini Balaji, PhD; Phone Number: 00914443968888; Email: bhavadharini.balaji@gmail.com
      • Principal Investigator: V Mohan, PhD
      • Sub-Investigator: Uma Ram, FRCOG
      • Sub-Investigator: Ranjit M Anjana, PhD
      • Sub-Investigator: Deepa Mohan, PhD
• Kenya
  • Eldoret, Kenya
    • Recruiting
    • Moi University School of Medicine & Teaching and Referral Hospital
    • Contact: Sonak Pastakia, DPharm MPH; Phone Number: 00254729027569; Email: spastaki@gmail.com
    • Contact: Wycliffe Kosgei, MBBS, MMed; Phone Number: 00254723758638; Email: wycliffe.kosgei@gmail.com
    • Principal Investigator: Sonak Pastakia, DPharm MPH
    • Sub-Investigator: Astrid Christoffersen-Deb, MRCOG PhD
    • Sub-Investigator: Wycliffe Kosgei, MBBS, MMed
    • Sub-Investigator: Beryl Onyango, BPharm

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

• Sampling Method: Probability Sample

Study Population

The project will be set in and around Chennai (Tamil Nadu, South India) and Eldoret (Western Kenya). Two independent cohorts will be formed, comprising of 3400 and 4000 pregnant women in early pregnancy in India and Kenya, respectively.

Description

Inclusion Criteria:

• All pregnant women between the age of 18 and 50 years of age

Exclusion Criteria:

• Women presenting beyond 16 weeks of gestation Known Type 1 or Type 2 diabetes
• Severe anaemia defined as haemoglobin (Hb) <8g/L and
• Sickle cell traits, sickle cell anaemia and other genetic Hb variants
• Women on Metformin therapy for anovulation and/or infertility

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Asian Indian; Recruitment to the Indian cohort will be carried out in urban areas of Chennai and be coordinated from Madras Diabetes Research Foundation (MDRF). As a part of their routine care, all pregnant women will undergo regular blood tests at presentation, a dating scan if the last menstrual period is unknown and an ultrasound at 20 weeks of pregnancy for foetal anomalies. 3400 pregnant women in early pregnancy will be studied in this cohort.
African; Recruitment to the Kenyan cohort will be based and coordinated from Moi Teaching and Referral hospital (MTRH). The bulk of the recruitment will happen at MTRH with significant contribution from Usain Gisu District hospital (UGDH) and Medi-Heal. 4000 pregnant women in early pregnancy will be studied in this cohort.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Development and validation of composite risk score for GDM with the risk factors of interest and/or point-of-care HbA1c	3 YEARS

Secondary Outcome Measures

Outcome Measure	Time Frame
Identification and the impact of other novel risk factors on the diagnosis of GDM and other adverse maternal outcomes	3 YEARS

Collaborators and Investigators

• Sponsor: University of Warwick
• Collaborators: Moi Univeristy; Madras Diabetes Research Foundation
• Investigators: Principal Investigator: Ponnusamy Saravanan, FRCP PhD, University of Warwick

Study record dates

Study Major Dates

• Study Start: February 1, 2016
• Primary Completion (ANTICIPATED): July 1, 2018
• Study Completion (ANTICIPATED): January 1, 2019

Study Registration Dates

• First Submitted: December 22, 2016
• First Submitted That Met QC Criteria: December 22, 2016
• First Posted (ESTIMATE): December 29, 2016

Study Record Updates

• Last Update Posted (ESTIMATE): December 30, 2016
• Last Update Submitted That Met QC Criteria: December 29, 2016
• Last Verified: December 1, 2016

More Information

Terms related to this study

• Keywords: Screening, diagnosis, risk stratification, ethnic
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Pregnancy Complications; Diabetes Mellitus; Diabetes, Gestational
• Other Study ID Numbers: MRMV0135

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Metadata will be archived following the publication of the study findings as per MRC UK's guidelines